Muroya Daisuke, Nishimura Taro, Kanno Hiroki, Kojima Satoki, Fukutomi Shogo, Akashi Masanori, Nomura Yoriko, Goto Yuichi, Sato Toshihiro, Sakai Hisamune, Hisaka Toru, Akagi Yoshito, Okuda Koji
Department of Surgery, Kurume University School of Medicine.
Kurume Med J. 2023 Apr 4;68(1):9-18. doi: 10.2739/kurumemedj.MS681001. Epub 2023 Feb 8.
Several studies have reported that interferon (IFN) therapy improves the prognosis of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), especially for patients who have achieved a sustained virological response (SVR). We retrospectively evaluated the clinicopathological outcomes of patients who acquired an SVR through IFN therapy pre- or post-hepatectomy for treatment naïve HCC.
Among the 305 HCV-related HCC patients entered in this study, 59 patients (SVR group) achieved an SVR after IFN therapy and received hepatectomy either after or before achieving an SVR (n=36 and n=23, respectively), while the remaining 179 patients (control group) did not receive IFN therapy, or did not achieve an SVR through IFN therapy (n=67).
In the SVR group, the overall survival (OS) and disease-free survival (DFS) rates were significantly higher than in the control group. We evaluated the prognosis of patients with an SVR achieved pre- or post-hepatectomy separately. There were no significant differences in OS and DFS.
This result suggests that the prognosis of naïve HCC may be improved by additional INF therapy to achieve SVR status after hepatectomy.
多项研究报告称，干扰素（IFN）治疗可改善丙型肝炎病毒（HCV）相关肝细胞癌（HCC）患者的预后，尤其是对于实现持续病毒学应答（SVR）的患者。我们回顾性评估了初治HCC患者在肝切除术前或术后通过IFN治疗获得SVR的患者的临床病理结局。
在本研究纳入的305例HCV相关HCC患者中，59例患者（SVR组）在IFN治疗后获得SVR，并在获得SVR后（n = 36）或之前（n = 23）接受了肝切除术，而其余179例患者（对照组）未接受IFN治疗，或未通过IFN治疗获得SVR（n = 67）。
SVR组的总生存期（OS）和无病生存期（DFS）率显著高于对照组。我们分别评估了肝切除术前或术后获得SVR的患者的预后。OS和DFS无显著差异。
该结果表明，初治HCC患者在肝切除术后通过额外的INF治疗实现SVR状态可能改善预后。
